Translational Drug Development
Translational Drug Development (TD2), based in Scottsdale, AZ, is an oncology development organization that provides innovative services for oncology-focused companies. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments.
Related Websites
Related News & Events
- 9.4.2024: Translational Drug Development (TD2) Expands Clinical Trial Services into Europe
- 2.1.2024: TD2 Expands Preclinical and Clinical Services by Acquiring Flow Contract Site Laboratory (FCSL)
- 10.5.2022: TD2 Announces Dr. Alan Miller as New Chief Medical Officer
- 4.5.2022: TD2 Highlights Two Novel HDAC Inhibitors at AACR Annual Meeting
- 9.16.2021: TD2 and Deep Lens Partner to Accelerate Clinical Trial Enrollment for Oncology Clinical Trials
- 6.4.2020: RCT Acquires Translational Drug Development, LLC
